Telo Genomics Corp. (TSXV:TELO)

Market Cap	5.02M -51.9%
Revenue (ttm)	n/a
Net Income	-2.62M
EPS	-0.03
Shares Out	100.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,379
Average Volume	100,555
Open	0.0500
Previous Close	0.0500
Day's Range	0.0500 - 0.0500
52-Week Range	0.0400 - 0.1250
Beta	0.18
RSI	51.12
Earnings Date	Feb 25, 2026

About Telo Genomics

Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company’s TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability, identify specific disease mechanisms, predict disease risks, and determine effective treatments. Its lead product is TeloView-SM...

• Industry: Diagnostics & Research
• Sector: Healthcare
• CEO: Sabine Mai
• Employees: 6
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: TELO